Search clinical trials for: Human papillomavirus vaccine

Total 31216 results

AIDS Malignancy Consortium
National Cancer Institute (NCI); Merck Sharp & Dohme LLC; University of Arkansas and other collaborators

Completed

Vaccine Therapy in Preventing Human Papillomavirus Infection in Young HIV-Positive Male Patients Who Have Sex With Males

Precancerous Condition | Anal Cancer | Penile Cancer | Nonneoplastic Condition

United States, Puerto Rico
GlaxoSmithKline

Completed

Evaluation of Safety and Immunogenicity of a Human Papillomavirus (HPV) Vaccine in Human Immunodeficiency Virus (HIV) Infected Females

Infections, Papillomavirus | Papillomavirus Vaccines

Thailand, Estonia, India, Brazil
Universiteit Antwerpen
Amsterdam UMC, location VUmc; Novosanis NV; Self-screen B.V.

Completed

CASUS: Improved and Quality Assured Collection of First-void Urine (CASUS-WP1)

Cervical Cancer | Cervical Intraepithelial Neoplasia | HPV-Related Cervical Carcinoma | Urine | Human Papilloma Virus

Belgium
Xiamen University
Xiamen Innovax Biotech Co., Ltd; Beijing Wantai Biological Pharmacy Enterprise...

Completed

Clinical Trial of Recombinant Human Papillomavirus Virus 16/18 Bivalent Vaccine

Cervical Cancer

China
University of Witwatersrand, South Africa
Merck Sharp & Dohme LLC

Completed

Randomized, Double Blind Trial of the Quadrivalent HPV Vaccine to Improve Responses to LEEP Treatment of Cervical HSIL

Cervical High Grade Squamous Intraepithelial Lesion
GlaxoSmithKline

Completed

Evaluation of Immunogenicity and Safety of Two 2-dose Human Papillomavirus (HPV) Vaccine Schedules in 9-14 Year Old Girls

Infections, Papillomavirus

Germany, Taiwan, Thailand, Canada, Italy
University of Florida

Completed

A Multilevel Approach to Increasing HPV Vaccine Initiation Among Adolescents - Part 3

Human Papilloma Virus

United States
University of Florida

Completed

Usability of HPV Vaccine Reminders

Human Papilloma Virus (HPV)

United States
University of Texas Southwestern Medical Center
National Cancer Institute (NCI); Southern Methodist University; Parkland Health...

Completed

Developing a Self-persuasion Intervention Promoting Adolescent HPV Vaccination

Human Papillomavirus Vaccines

United States
University of North Carolina, Chapel Hill
Centers for Disease Control and Prevention; New York State Department of Health and other collaborators

Completed

Quality Improvement Strategies to Increase Human Papillomavirus (HPV) Vaccination

Human Papillomavirus Infection

United States
GlaxoSmithKline

Completed

Safety and Immunogenicity of GSK Biologicals' HPV-16/18 L1 VLP AS04 Vaccine (GSK-580299) in Healthy Female Children 4-6 Years Old

Infections, Papillomavirus

Panama, Mexico, Colombia
University of Texas Southwestern Medical Center
Cancer Prevention Research Institute of Texas; Parkland Health and Hospital...

Completed

An Intervention Promoting HPV Vaccination in Safety-net Clinics

Human Papilloma Virus-Related Cervical Carcinoma

United States
Augusta University

Unknown

9-valent HPV Vaccine in Postpartum Women

Human Papilloma Virus
Laval University

Completed

Immunogenicity of Gardasil and Twinrix and the Effect of a Dose of Gardasil or Cervarix Given 42 Months Later.

Human Papillomavirus

Canada
University of North Carolina, Chapel Hill
Centers for Disease Control and Prevention; American Cancer Society, Inc.; New... and other collaborators

Withdrawn

Quality Improvement Strategies to Increase Human Papillomavirus (HPV) Vaccination in Integrated Healthcare Delivery Systems

Human Papillomavirus Infection

United States
Xiamen University
Ministry of Science and Technology of the People´s Republic of China; Xiamen... and other collaborators

Completed

Efficacy and Immunogenicity Study of Recombinant Human Papillomavirus Bivalent（Type 16/18 ）Vaccine

Cervical Cancer | Cervical Intraepithelial Neoplasia | Vaginal Intraepithelial Neoplasia | Vulvar Intraepithelial Neoplasia | Persistent Infection

China
University of California, Los Angeles
Cedars-Sinai Medical Center

Completed

Increasing Human Papillomavirus (HPV) Vaccine Uptake Via General Health Messaging

Human Papilloma Virus

United States
University Hospital Virgen de las Nieves
Instituto de Salud Carlos III

Unknown

Immunogenicity and Safety of a 9-valent Human Papillomavirus Vaccine in HIV-positive Women (9-VPH-MVIH)

HIV Infections | HPV Infection

Spain
GlaxoSmithKline

Completed

Evaluation of Long-term Immunogenicity and Safety of a Human Papillomavirus (HPV) Vaccine in Healthy Female Subjects.

Infections, Papillomavirus | Papillomavirus Vaccines

Germany, Taiwan, Colombia, Panama, Honduras
GlaxoSmithKline

Completed

Immunogenicity and Safety of a Commercially Available Vaccine Co-administered With GSK HPV Vaccine (580299)

Infections, Papillomavirus | Papillomavirus Vaccines

Belgium
GlaxoSmithKline

Completed

Safety and Immunogenicity of GlaxoSmithKline Biologicals' HPV Vaccine 580299 (Cervarix) in HIV Infected Females

Infections, Papillomavirus

South Africa
GlaxoSmithKline

Completed

Study to Evaluate the Efficacy of the Human Papillomavirus Vaccine in Healthy Adult Women of 26 Years of Age and Older

Infections, Papillomavirus | Papillomavirus Vaccines

United States, Russian Federation, Canada, Singapore, Netherlands, United Kingdom, Thailand, Australia, Philippines, Mexico, Portugal, Peru
GlaxoSmithKline

Completed

Human Papillomavirus Vaccine Immunogenicity and Safety Trial in Young Adult Women With GSK Biologicals Novel HPV Vaccine

Infections, Papillomavirus | Papillomavirus Vaccines

Belgium, United States
GlaxoSmithKline

Completed

Immunogenicity of GlaxoSmithKline Biological's Human Papillomavirus (HPV) Vaccine (580299) Versus Merck's Gardasil® in Healthy Females 18-45 Years of Age

Infections, Papillomavirus | Papillomavirus Vaccines

United States
GlaxoSmithKline

Completed

Human Papilloma Virus Vaccine Immunogenicity and Safety Trial in Young Adult Women With GSK Bio's Novel HPV Vaccine.

Infections, Papillomavirus

Belgium, United States
GlaxoSmithKline

Completed

Human Papilloma Virus (HPV) Vaccine Immunogenicity and Safety Trial in Young and Adult Women With GSK Biologicals' HPV-16/18

Infections, Papillomavirus

Germany, Poland
Merck Sharp & Dohme LLC

Completed

Immunogenicity and Tolerability of Broad Spectrum Human Papillomavirus (HPV) Vaccine in Adult and Young Adult Women (V503-004)

Cervical Cancer | Vulvar Cancer | Vaginal Cancer | Human Papillomavirus Infection | Genital Warts

Austria, Belgium, Finland, Germany, Italy, Spain
Hospital San Carlos, Madrid
Merck Sharp & Dohme LLC

Unknown

Retrospective Cohort Study of the Effectiveness of the Prophylactic Vaccine Against the Human Papilloma Virus in the Prevention of Recurrence in Women Who Have Received an Excisional Therapy by HSIL / CIN. (VENUS)

HPV Infection | HPV Vaccine | Cervix Lesion | Cervix, Dysplasia

Spain
GlaxoSmithKline

Completed

Immunogenicity and Safety Study of GlaxoSmithKline Biologicals' Human Papillomavirus (HPV) Vaccine (GSK-580299) and Merck's Gardasil Vaccine When Administered According to Alternative 2-dose Schedules in 9-14 Year Old Females

Infections, Papillomavirus

Singapore, Hong Kong, France, Sweden
GlaxoSmithKline

Terminated

A Study to Assess the Safety and Reactogenicity of GlaxoSmithKline (GSK) Biologicals' Human Papillomavirus (HPV) Vaccine (Cervarix) in Healthy Female Filipino Subjects Vaccinated According to the Prescribing Information From the Age of 10 Years Onwards.

Human Papillomavirus Infection Leading to Cervical Cancer

Philippines
GlaxoSmithKline

Completed

Gynaecological Follow-up of a Subset of HPV-015 (NCT00294047) Study Subjects

Infections, Papillomavirus

United States, Canada, Singapore, Netherlands, United Kingdom, Russian Federation, Portugal
GlaxoSmithKline

Completed

Gynaecological Follow-up of a Subset of 580299/008 (NCT00122681) Study Subjects

Infections, Papillomavirus

United States, Australia, Finland, Germany, Taiwan, Belgium, Spain, Canada, Thailand, Italy, United Kingdom, Brazil, Philippines
University of California, Los Angeles
Los Angeles County Department of Public Health

Completed

Increasing Human Papillomavirus Vaccine Uptake in Low-Income, Ethnic Minority Adolescents in Los Angeles County

Human Papilloma Virus Infection

United States
Saglik Bilimleri Universitesi Gulhane Tip Fakultesi

Completed

The Effects of Health Education About Human Papilloma Virus and Cervical Cancer Prevention on Knowledge, Attitudes, Beliefs and Behaviors

Health Education

Turkey
Tufts University

Completed

Promoting HPV Vaccine Through Twitter

Human Papilloma Virus
Kenya Medical Research Institute
Merck Sharp & Dohme LLC; University of Washington

Completed

A Cohort Study to Assess Sustained Immunogenicity to qHPV Vaccine Among HIV-infected Girls and Boys Age 9-14 Years

HIV-1 Infection | Human Papillomavirus
University of Colorado, Denver
Centers for Disease Control and Prevention

Completed

Strengthening Physician Communication About HPV Vaccines

HPV Immunization Status

United States
GlaxoSmithKline

Completed

Efficacy, Immunogenicity and Safety of GSK Biologicals' HPV GSK 580299 Vaccine in Healthy Chinese Female Subjects

Infections, Papillomavirus

China
Indiana University

Completed

An Evaluation of Tailored Messages to Address Parental Questions About HPV Vaccination

Attitude to Health | Human Papilloma Virus Vaccines

United States
Merck Sharp & Dohme LLC

Completed

Efficacy and Tolerability Study of V501 in Japanese Males (V501-122)

Condyloma Acuminata | Anogenital Human Papilloma Virus Infection
Public Health England

Completed

Observational Follow up of Prior HPV Vaccinees (HPVfollowup)

Human Papillomavirus Virus

United Kingdom
Shenzhen People's Hospital

Unknown

DC Vaccines Targeting HPV16/18 E6/E7 Protein to Regress CINI/CIN2

Cervical Intraepithelial Neoplasia

China
GlaxoSmithKline

Completed

Vaccine To Prevent Cervical Intraepithelial Neoplasia or Cervical Cancer in Younger Healthy Participants

Cervical Cancer | Precancerous Condition

Costa Rica
Merck Sharp & Dohme LLC

Completed

Prevention of Human Papillomavirus (HPV) in 20 to 45 Year Old Chinese Women (V501-041)

HPV Infections
Jun Zhang
Xiamen Innovax Biotech Co., Ltd; Beijing Wantai Biological Pharmacy Enterprise...

Completed

Immuno-persistence Study of a Recombinant Human Papillomavirus 16/18 Bivalent Vaccine in Preadolescent Girls

Cervical Cancer | Cervical Intraepithelial Neoplasia | Vaginal Intraepithelial Neoplasia | Vulvar Intraepithelial Neoplasia | Persistent Infection

China
Merck Sharp & Dohme LLC

Completed

Immunogenicity and Tolerability of V503 Versus GARDASIL (V503-009)

Human Papillomavirus
Merck Sharp & Dohme LLC

Completed

A Study of the Safety, Tolerability, and Immunogenicity of a 9-valent Human Papillomavirus Vaccine ([9vHPV]; V503) Administered to 9- to 15-Year-Old Japanese Girls (V503-008).

Papillomavirus Infections
Merck Sharp & Dohme LLC

Completed

Broad Spectrum HPV (Human Papillomavirus) Vaccine Study in 16-to 26-Year-Old Women (V503-001)

Cervical Cancer | Vulvar Cancer | Vaginal Cancer | Human Papillomavirus Infection | Genital Warts
Merck Sharp & Dohme LLC

Completed

Multivalent HPV (Human Papillomavirus) Vaccine Study in 16- to 26-Year Old Men and Women (V503-003)

Anal Cancer | Genital Warts | Anal Intraepithelial Neoplasia
Merck Sharp & Dohme LLC

Completed

A Study of V503, a 9-valent Human Papillomavirus (9vHPV) Vaccine in Females 12-26 Years of Age Who Have Previously Received GARDASIL™ (V503-006)

Genital Warts | Cervical Cancers | Vulvar Cancers | Vaginal Cancers

Search clinical trials for: Human papillomavirus vaccine

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Mauritania

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations